134.56
前日終値:
$133.23
開ける:
$133.26
24時間の取引高:
159.61K
Relative Volume:
0.17
時価総額:
$13.35B
収益:
$2.41B
当期純損益:
$305.80M
株価収益率:
45.61
EPS:
2.95
ネットキャッシュフロー:
$492.20M
1週間 パフォーマンス:
+2.53%
1か月 パフォーマンス:
+2.12%
6か月 パフォーマンス:
+11.55%
1年 パフォーマンス:
-10.78%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NBIX
Neurocrine Biosciences Inc
|
134.63 | 13.21B | 2.41B | 305.80M | 492.20M | 2.95 |
![]()
ZTS
Zoetis Inc
|
156.75 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.34 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
![]()
HLN
Haleon Plc Adr
|
9.825 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.50 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
310.94 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-21 | 開始されました | Truist | Buy |
2025-07-10 | 開始されました | Goldman | Buy |
2025-04-15 | アップグレード | Needham | Hold → Buy |
2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2025-02-11 | 開始されました | Deutsche Bank | Hold |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2023-12-13 | 再開されました | Citigroup | Neutral |
2023-12-12 | 開始されました | Deutsche Bank | Buy |
2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
2023-08-21 | 繰り返されました | Mizuho | Neutral |
2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
2022-10-11 | 開始されました | UBS | Buy |
2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
2022-06-06 | 再開されました | Jefferies | Buy |
2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-02-25 | アップグレード | Goldman | Neutral → Buy |
2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-09-23 | 再開されました | Needham | Hold |
2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
2021-05-18 | 再開されました | Goldman | Neutral |
2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
2021-02-02 | 開始されました | Raymond James | Outperform |
2020-09-30 | 開始されました | The Benchmark Company | Hold |
2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
2020-06-09 | 開始されました | Wedbush | Outperform |
2020-03-06 | 開始されました | Citigroup | Buy |
2020-02-27 | 開始されました | Barclays | Equal Weight |
2020-02-24 | 開始されました | William Blair | Outperform |
2020-02-06 | 開始されました | Mizuho | Neutral |
2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
2019-07-16 | 開始されました | Oppenheimer | Outperform |
2019-06-05 | 開始されました | Guggenheim | Neutral |
2019-05-21 | 開始されました | Credit Suisse | Outperform |
2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
2019-04-12 | 開始されました | Evercore ISI | Outperform |
2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
2018-12-13 | 開始されました | Goldman | Buy |
2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Singer Carnie Wilson and Dr. Greg Mattingly discuss tardive dyskinesia on Your Day - WKEF
Will Neurocrine Biosciences Inc. stock go up soonTrend Reversal & AI Enhanced Execution Alerts - Newser
Published on: 2025-08-20 04:48:02 - classian.co.kr
Will Neurocrine Biosciences Inc. price bounce be sustainableEarnings Overview Report & Precise Trade Entry Recommendations - Newser
Long term hold vs stop loss in Neurocrine Biosciences Inc.Weekly Trading Summary & Daily Profit Focused Stock Screening - Newser
How to integrate Neurocrine Biosciences Inc. into portfolio analysis toolsPortfolio Return Report & Precise Trade Entry Recommendations - Newser
Using portfolio simulators with Neurocrine Biosciences Inc. included2025 Performance Recap & Verified Trade Idea Suggestions - Newser
Does Neurocrine Biosciences Inc. fit your quant trading modelJuly 2025 Action & Community Consensus Picks - Newser
Real time scanner hits for Neurocrine Biosciences Inc. explainedRate Cut & Daily Profit Maximizing Trade Tips - Newser
Relative strength of Neurocrine Biosciences Inc. in sector analysisPortfolio Performance Report & Reliable Intraday Trade Plans - Newser
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q1 2025 Earnings Call Transcript - MSN
Order flow analysis tools used on Neurocrine Biosciences Inc.2025 Buyback Activity & Daily Profit Focused Screening - Newser
Ranking Neurocrine Biosciences Inc. among high performing stocks via toolsWeekly Gains Summary & Breakout Confirmation Trade Signals - Newser
Will Neurocrine Biosciences Inc. stock recover after recent dropJuly 2025 PostEarnings & Weekly Chart Analysis and Guides - Newser
Is Neurocrine Biosciences Inc. stock reversal real or fakeQuarterly Earnings Report & Weekly Market Pulse Updates - Newser
Top chart patterns to watch in Neurocrine Biosciences Inc.Dollar Strength & AI Enhanced Trading Alerts - Newser
What’s the recovery path for long term holders of Neurocrine Biosciences Inc.2025 Historical Comparison & Risk Adjusted Buy and Sell Alerts - Newser
Published on: 2025-08-16 23:41:15 - Newser
Understanding Neurocrine Biosciences Inc.’s price movementTrade Performance Summary & Fast Exit and Entry Strategy Plans - Newser
Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - MSN
Visual analytics tools that track Neurocrine Biosciences Inc. performancePortfolio Value Summary & Low Risk Entry Point Tips - Newser
Reversal Traders Monitor Neurocrine Biosciences Inc. for EntryJuly 2025 Institutional & Weekly Sector Rotation Insights - metal.it
Trendlines Converge — Decision Point for Neurocrine Biosciences Inc.July 2025 Recap & Stock Market Timing Techniques - beatles.ru
Real time social sentiment graph for Neurocrine Biosciences Inc.2025 Big Picture & Technical Confirmation Alerts - Newser
Earnings visualization tools for Neurocrine Biosciences Inc.2025 Price Targets & Precise Trade Entry Recommendations - Newser
Published on: 2025-08-15 16:55:58 - Newser
PNC Financial Services Group Inc. Cuts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
What Technical Tools Say About Neurocrine Biosciences Inc. RecoveryJuly 2025 Macro Moves & Weekly High Return Stock Opportunities - newsimpact.co.kr
Neurocrine at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
US Bancorp DE Has $412,000 Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Stronger-Than-Expected Q2 Results Could Be a Game Changer for Neurocrine Biosciences (NBIX) - simplywall.st
Neurocrine Biosciences Director Gorman Buys, Sells 106,322 Shares on 8/7/2025 - AInvest
Neurological Disorder Drugs Market Set to Witness Significant - openPR.com
Will Neurocrine Biosciences Inc. bounce back from current supportWatchlist Summary for Active Day Traders - Newser
What’s next for Neurocrine Biosciences Inc. stock priceFree Daily Growth Stock Pick Reports - Newser
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 - GlobeNewswire Inc.
Neurocrine Biosciences shares rise 3.11% after-hours following Nxera Pharma's obesity pipeline progress. - AInvest
This Neurocrine Biosciences Insider Reduced Their Stake By 28% - 富途牛牛
Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference - Yahoo Finance
Neurocrine Biosciences shares fall 1.10% intraday as Nxera Pharma launches obesity drug pipeline. - AInvest
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Tardive Dyskinesia Drugs Market Exclusive Report with Detailed - openPR.com
Neurocrine Biosciences (NASDAQ:NBIX) Upgraded at Wall Street Zen - Defense World
Guggenheim Boosts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $175.00 - MarketBeat
CRENESSITY's Breakout Launch Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
William Blair Analysts Increase Earnings Estimates for NBIX - Defense World
What drives Neurocrine Biosciences Inc. stock priceUnlock powerful trading alerts for success - Jammu Links News
Is Neurocrine Biosciences Inc. a growth stock or a value stockTremendous wealth creation - Jammu Links News
Neurocrine Biosciences Inc. Stock Analysis and ForecastRapid portfolio appreciation - Jammu Links News
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $144.00 at Royal Bank Of Canada - MarketBeat
How does Neurocrine Biosciences Inc. generate profit in a changing economyMaximize portfolio value with smart investment plans - Jammu Links News
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
Neurocrine Biosciences Inc (NBIX) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
GORMAN KEVIN CHARLES | Director |
Aug 07 '25 |
Sale |
126.41 |
106,322 |
13,440,281 |
514,596 |
大文字化:
|
ボリューム (24 時間):